- All
- News - 2026
News
14 July, 2026
Hummingbird Bioscience, a biotherapeutics company discovering and developing transformative medicines for diseases with significant unmet need, has won the Asia Pacific Trailblazer Award at the 2026 AI Discovery Awards hosted by Nebius.
News
6 January, 2026
Hummingbird Bioscience today announced that the first patient has been dosed in a Phase I clinical trial of HMBD-501 for the treatment of patients with advanced HER3-expressing solid malignancies
News
26 June, 2025
Percheron Therapeutics obtains exclusive worldwide rights to Hummingbird Bioscience’s HMBD-002 for further clinical development
News
7 May, 2025
Hummingbird Bioscience, a biotherapeutics company discovering and developing transformative medicines for hard-to-treat diseases, today announced the internal appointment of Dipti Thakkar, PhD, as Chief Operating Officer.
News
3 March, 2025
Callio Therapeutics, a biotechnology company focused on realizing the promise of multi-payload antibody-drug conjugates (ADCs) to improve cancer therapy, today announced its launch with the closing of a $187.0 million Series A financing round.
News
7 January, 2025
Hummingbird Bioscience, a precision biotherapeutics company discovering and developing transformative biologics for hard-to-treat diseases, today announced it has granted Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, an exclusive, worldwide license to monoclonal antibodies that are directed to a single undisclosed target.
News
23 October, 2024
Hummingbird Bioscience, a precision biotherapeutics company discovering and developing transformative biologics for hard-to-treat diseases, today announced a poster presentation on HMBD-802, a novel first-in-class dual-payload anti-HER2 antibody-drug conjugate, at the 36th EORTC-NCI-AACR symposium (23-25 October 2024).
News
29 July, 2024
Hummingbird Bioscience, a precision biotherapeutics company discovering and developing transformative biologics for hard-to-treat diseases, today announced the internal appointments of Kon Yew Kwek, BM BCh, DPhil, and Lisa Ooi, PhD, as Chief Medical Officer and Chief Operating Officer, respectively.
News
13 May, 2024
Hummingbird Bioscience is presenting its next-generation antibody-drug conjugate capabilities at PEGS Boston 2024.
News
7 May, 2024
View recording of the 3rd Annual Virtual VISTA Symposium.
News
13 March, 2024
Hummingbird Bioscience and Dartmouth’s Geisel School of Medicine today announced that the 3rd Annual VISTA Symposium will take place virtually on Wednesday, March 27, 2024 (11:00 AM - 3:30 PM ET).
News
6 March, 2024
Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced two upcoming poster presentations at the American Association for Cancer Research (AACR) Meeting 2024 (April 5-10) in San Diego, California.
News
11 December, 2023
Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced the appointment of Angèle Maki, Ph.D., as Chief Business Officer, effective immediately.
News
23 October, 2023
Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced presentation of positive clinical data for the dose escalation part of the HMBD-001 Phase I/IIa trial (NCT05057013) at the European Society for Medical Oncology Congress 2023 (ESMO 2023). The trial is evaluating HMBD-001 as a monotherapy across various tumor types in the UK.
News
21 August, 2023
Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced an upcoming poster presentation at the IASLC 2023 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer (9-12 September 2023, Singapore). The poster will highlight the scientific rationale for combining anti-HER3 antibody HMBD-001 with EGFR inhibition and chemotherapy to improve treatment outcomes in squamous non-small cell lung cancer (sqNSCLC).
News
27 July, 2023
Hummingbird Bioscience has initiated two clinical trials in Australia evaluating HMBD-001 in patients with squamous non-small cell lung cancer and patients with genetic aberrations in HER3 signaling. Hummingbird Bioscience has partnered with Omico to accelerate clinical development of HMBD-001, leveraging Omico’s PrOSPeCT initiative and network in Australia to recruit patients with gene signatures most likely to benefit from HMBD-001.
News
29 May, 2023
VISTA blockade with HMBD-002 reprograms tumor associated macrophages and promotes cytotoxic T-cell response in preclinical studiesHMBD-002 in combination with anti-PD-1 treatment shows enhanced anti-tumor efficacy compared to monotherapy arms in preclinical studies HMBD-002 is currently being assessed in a Phase 1 study to determine the recommended Phase 2 dose as a monotherapy and in combination […]
News
15 May, 2023
Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced it has entered into a clinical trial collaboration and supply agreement with Merck to evaluate HMBD-001 in combination with cetuximab in squamous non-small cell lung carcinoma
News
8 May, 2023
Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced an upcoming poster presentation at IMMUNOLOGY2023™
News
15 March, 2023
Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced two upcoming poster presentations at the American Association for Cancer Research (AACR) Meeting 2023 (April 14-19) in Orlando, Florida.
News
6 March, 2023
Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, and Cancer Research Horizons, the innovation arm of Cancer Research UK (CRUK), today announced that Hummingbird Bioscience has exercised its option to license in the first-in-human (FIH) clinical trial results of HMBD-001, a differentiated and potentially best-in-class HER3-targeting antibody.
News
4 January, 2023
Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, and Hummingbird Bioscience (Hummingbird Bio), a data-driven precision biotherapeutics company using its Rational Antibody Discovery (RAD) platform to discover and engineer antibodies against optimal yet elusive epitopes, thereby unlocking novel mechanisms of action, today announced that they entered into a licensing agreement that will enable Hummingbird Bio to develop a next generation ADC program using Synaffix technology.
News
6 December, 2022
Collaboration to leverage Caris’ comprehensive (WES/WTS) molecular profiling technologies and large clinico-genomic database to elucidate biomarkers associated with response to HMBD-001, with the goal to increase the probability of clinical successIRVING, Texas and SINGAPORE, December 6, 2022 – Caris Life Sciences®(Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to … Continue reading "Caris Life Sciences and Hummingbird Bioscience Enter Into Collaboration to Advance Clinical Development of Anti-HER3 Therapy"
News
7 November, 2022
VISTA blockade with HMBD-002 reprograms tumor associated macrophages and promotes cytotoxic T-cell response in preclinical studiesHMBD-002 in combination with anti-PD-1 treatment shows enhanced anti-tumor efficacy compared to monotherapy arms in preclinical studies HMBD-002 is currently being assessed in a Phase 1 study to determine the recommended Phase 2 dose as a monotherapy and in combination […]
News
1 November, 2022
San Francisco & Houston & Singapore, November 1, 2022 – Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced that Chief Financial Officer Josh House and Chief Development Officer Leah DiMascio will participate in one-on-one investor meetings at the Credit Suisse 31st Annual Global Healthcare Conference […]
News
23 September, 2022
News
23 September, 2022
San Francisco & Houston & Singapore, September 23, 2022 – Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced the official opening of its office and research facilities at the Singapore Science Park. Deputy Prime Minister and Coordinating Minister for Economic Policies Heng Swee Keat officiated […]
News
19 September, 2022
San Francisco & Houston & Singapore, September 19, 2022 – Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced that Jerome Boyd-Kirkup, Ph.D., Hummingbird Bioscience’s Chief Scientific Officer, will present at the 2nd Annual VISTA Symposium on September 23, 2022.“VISTA is a promising therapeutic target we […]
News
8 September, 2022
– HMBD-001 is a proprietary anti-HER3 antibody in an ongoing Phase 1 trial targeting multiple solid tumors– HMBD-001 has the potential to fully block both ligand-dependent and -independent HER3 signalingSan Francisco & Houston & Singapore, September 8, 2022 – Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, […]
News
6 September, 2022
San Francisco & Houston & Singapore, September 6, 2022 – Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced that Chief Executive Officer Piers Ingram, Ph.D., and Chief Financial Officer Josh House will participate in one-on-one investor meetings at Morgan Stanley’s 20th Annual Global Healthcare Conference […]
News
9 February, 2022
Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets in cancer and autoimmune disease, today announced the publication of preclinical data for HMBD-002, a novel anti-VISTA antibody therapeutic, in the Journal for ImmunoTherapy of Cancer, a peer-reviewed journal of the Society for Immunotherapy of Cancer.
News
6 December, 2021
Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets in cancer and autoimmune disease, and Cancer Research UK, the world’s leading cancer charity, today announced that the first patient has been dosed in a Phase 1 clinical trial of HMBD-001 for the treatment of patients with advanced HER3-expressing solid malignancies (NCT05057013).
News
29 November, 2021
Hummingbird Bioscience Holdings Limited, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets in cancer and autoimmune disease, today announced the appointment of Jan Møller Mikkelsen as Chairman of its Board of Directors.
News
10 November, 2021
Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, today announced a Trials in Progress poster presentation outlining the Phase 1 clinical trial design for HMBD-002, a unique anti-VISTA antibody developed using Hummingbird’s Rational Antibody Discovery platform to address VISTA-mediated suppression of anti-tumor immune responses, at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). The meeting will be held in Washington, D.C. and virtually from November 10 to 14, 2021.
News
25 October, 2021
Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets to improve treatment outcomes, today announced it has entered into a clinical trial collaboration agreement with Merck.
News
7 October, 2021
Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, today announced the presentation of pre-clinical data on novel biomarkers for HER3-driven cancers at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics 2021. The conference will take place from October 7 to 10, 2021.
News
23 September, 2021
Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, has opened its new office location at the Singapore Science Park. The new base strengthens its Singapore presence and complements its offices in the United States at Texas Medical Centre and South San Francisco.
News
13 September, 2021
Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, today announced that the U.S. Food and Drug Administration (FDA) has approved the initiation of a Phase 1 clinical trial of HMBD-002, Hummingbird’s anti-VISTA neutralizing antibody.
News
1 September, 2021
Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, today announced the appointment of Josh House as Chief Financial Officer, effective immediately.
News
2 August, 2021
Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, today announced that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the clinical trial application (CTA) to initiate first-in-human phase 1 trial of HMBD-001 in patients with advanced cancers.
News
26 July, 2021
Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, today announced that internationally renowned scientist and medical oncologist, Dr. Thomas J Lynch, Jr, MD, has been appointed to its Board as a Non-Executive Director, effective immediately.
News
12 July, 2021
Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets to produce major improvements in treatment outcomes, and The University of Texas MD Anderson Cancer Center today announced the launch of a multi-year strategic research collaboration to investigate and evaluate HMBD-002, Hummingbird’s VISTA antagonist antibody.
News
15 June, 2021
Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, today announced that its Chief Scientific Officer and co-founder, Dr Jerome Boyd-Kirkup, will be speaking at the 2021 virtual symposium “VISTA: A New Immune Checkpoint in Cancer, Autoimmunity and Beyond”, taking place on June 18, 2021.
News
9 June, 2021
Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, today announced a strategic partnership with Asian genomic sequencing and bioinformatics company Novogene Co., Ltd. (“Novogene”).
News
31 May, 2021
Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets today announced that its abstract reporting pre-clinical results from its V-domain immunoglobulin suppressor of T cell activation (VISTA) antibody, HMBD-002, has been selected for publication at the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held June 4-8, 2021.
News
27 May, 2021
Pharma Intelligence’s Insights speaks to Hummingbird CEO Piers Ingram following the Singapore-based company’s Series C financing round.
News
27 May, 2021
Hummingbird discusses our HER3 program and how we are tackling the challenges of therapeutics development.
News
27 May, 2021
Hummingbird discusses why cutting-edge digital tools and data-rich computational approaches play a powerful role in the development of precision biotherapeutics.
News
18 May, 2021
Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets to improve treatment outcomes, today announced the close of its US$125 million Series C financing round.
News
10 April, 2021
Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets to improve treatment outcomes, today announced that the company will be presenting pre-clinical data on its BCMA-TACI dual-specific T cell engager, HMBD-009, at the 2021 American Association for Cancer Research (AACR) Annual Meeting taking place 9-14 April.
News
24 February, 2021
Hummingbird discusses how systems biology and data science have advanced the understanding of disease, and how Hummingbird’s unique multidisciplinary approach unites the power of these two fields to create revolutionary therapies.
News
17 February, 2021
Hummingbird speaks to DealStreetAsia about Hummingbird’s overall drug development moving into clinical trials this year and why setting milestones drive future investments.
News
28 January, 2021
Hummingbird Bioscience has been recognized with the Most Promising Innovation title at Singapore’s SG:D Techblazer Awards 2020, the nation’s highest accolade for tech innovation.
News
12 January, 2021
The Business Times lists Hummingbird Bioscience as one of the Top 10 Startups to watch in Singapore in 2021.
News
17 December, 2020
Hummingbird Bioscience is collaborating with Tempus to advance HMBD-001, a differentiated anti-HER3 neutralizing antibody developed using Hummingbird’s Rational Antibody Discovery platform, into clinical trials in HER3-driven cancers, including those that harbor neuregulin 1 (NRG1) fusions. Read the full story on BioWorld.
News
14 December, 2020
Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing revolutionary therapies for hard-to-drug targets, today announced a collaboration with Tempus, a leader in artificial intelligence and precision medicine, to drive the development of Hummingbird’s lead clinical program, HMBD-001, as it advances into clinical trials in HER3-driven cancers, including those that harbor neuregulin 1 (NRG1) fusions.
News
17 November, 2020
A new Covid-19 treatment could become available in Singapore and beyond by early 2021 as homegrown biotech company Hummingbird Bioscience joins major names in making steps to combat the coronavirus.
News
24 August, 2020
Global business has faced unprecedented challenges over the past 12 months, particularly in 2020.
News
23 August, 2020
Global business has faced unprecedented challenges over the past 12 months, particularly in 2020.
News
25 July, 2020
The Parker Institute for Cancer Immunotherapy (PICI) announced today that John Connolly, Ph.D., has been named chief scientific officer (CSO). In this role, Connolly.
News
10 May, 2020
Hummingbird Bioscience, an innovative biotherapeutics company focused on the discovery and development of new breakthrough therapies, has closed an extended Series B funding round of US$25 million.
News
5 December, 2019
Hummingbird Bioscience, an innovative biotherapeutics company pioneering the discovery and development of new breakthrough precision antibody therapeutics for difficult-to-treat conditions, today announced that it has raised US$19 million in a Series B financing round.
News
16 September, 2019
Hummingbird Bioscience, an innovative systems-biology enabled biotechnology company, has today announced a multi-target collaboration to co-discover novel antibody therapeutics with Amgen. This partnership brings together Hummingbird’s proprietary drug discovery platform with Amgen’s disease expertise and drug development capabilities.
News
8 August, 2019
Cancer Research UK, the world’s leading cancer charity, and Hummingbird Bioscience, an innovative systems-biology enabled biotechnology company, have today (Thursday) announced a partnership to develop Hummingbird’s anti-HER3 antibody drug, HMBD-001, for the treatment of people with HER3 driven cancer.
News
25 February, 2019
Hummingbird Bioscience announced today it has been awarded a product development grant totalling $13.1 million by the Cancer Prevention and Research Institute of Texas (CPRIT).
News
18 February, 2019
Hummingbird Bioscience, a systems-biology enabled biotech company focused on the discovery and development of novel cancer therapeutics, today announced James P. Allison, Ph.D. and Padmanee Sharma, M.D., Ph.D., have joined its Scientific Advisory Board.
News
9 November, 2018
Hummingbird Bioscience, a systems biology powered drug discovery and development company focused on novel cancer therapeutics, will present a poster “HMBD-002-V4: A novel anti-VISTA antibody that uniquely neutralizes VISTA activity and potently inhibits tumor growth by remodeling an immunosuppressive tumor microenvironment” at the Society for Immunotherapy of Cancer Annual Meeting taking place in Washington D.C. on November 9-11, 2018.
News
5 November, 2018
Hummingbird Bioscience, a systems biology powered drug discovery and development company focused on novel cancer therapeutics, will present a poster “HMBD-002-V4: A novel anti-VISTA antibody that uniquely neutralizes VISTA activity and potently inhibits tumor growth by remodeling an immunosuppressive tumor microenvironment” at the Society for Immunotherapy of Cancer Annual Meeting taking place in Washington D.C. on November 9-11, 2018.
News
10 April, 2018
Hummingbird Bioscience, a drug discovery and development company focused on novel cancer immuno-therapeutics, will present a poster “HMBD-002-V4, an Anti-VISTA Neutralizing Antibody, Displays Potent Anti-Tumor Efficacy in Combination with Anti-PD(L)1, Through Release of MDSC Mediated Immunosuppresion in the TME” at the American Association for Cancer Research Annual Meeting in Chicago taking place from 14-18 April, 2018.
News
3 May, 2017
Hummingbird is focused on applying advances in systems biology to rapidly develop antibodies into successful cancer therapeutics. The company will use the funds raised to advance its lead programs towards the clinic with plans to submit the first IND in 2018. The programs in question; HMBD-001 targeting a novel mechanism on HER3, and HMBD-002 targeting a novel epitope on VISTA, have already shown great promise in early animal studies.
